Guangyu Li, M.D., Ph.D.
Department of Internal Medicine
Division of Infectious Diseases
301 University Blvd, Mary Moody Northen, Rm 5.410
Galveston, Texas 77555-0435
|Degree/Training Completed||Year||Name & Location|
|M.D.||1997||Fourth Military Medical University, Xi'an, China|
|Ph.D.||2005||Fourth Military Medical University, Xi'an, China|
|Postdoctoral Fellow||2011||University of Texas Medical Branch, Galveston, USA|
Dr. Li joined UTMB in 2005. After 5 years postdoctoral training in Departments Of Pathology and Internal Medicine at UTMB, he got a faculty position as an instructor in Division of Infectious diseases. Dr. Li's research area is on several key aspects of emerging and serious infectious diseases, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), hemorrhagic fever with renal syndrome virus (HFRSV) and Yellow Fever virus (YFV). He has made numerous contributions to the field of virology. In recent years, his research has focused on the pathogenesis of HIV and HCV, serious problems and challenges for human health.
Many viruses establish chronic infections that persist for the lifetime of their hosts. Some of these viruses, including HIV and HCV, are associated with a large degree of worldwide morbidity and mortality. Current therapies for these diseases are only moderately effective, and are often limited by a number of variables including cost, significant side effects, and viral resistance to the drugs. Therefore, new and improved therapies for these diseases are needed. Our laboratory studies the host-pathogen interactions related to HCV/HIV infection.
- HCV infection leads to millions of deaths each year from liver diseases such as cirrhosis and hepatocellular carcinoma. We are exploring a unique therapeutic approach to treat this disease. We are characterizing the ability of novel antiviral and immunomodulatory cytokines to inhibit HCV replication and prevent liver damage. In addition, we are studying new methodologies to boost the immune response to HCV in people who are chronically infected.
- We are also trying to uncover new cellular restriction factors and mechanisms of intracellular factors to HIV-1. CD63 is one of identified cellular factors which involves in HIV-1 restriction in human macrophages. ADAM10 is another cellular factor which is firstly identified by our lab. The search for novel viral restriction factors have the potential to expand the repertoire of antiviral therapies beyond those currently being employed, and therefore significantly impact public health.